Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Osiris Therapeutics, Inc.    OSIR

Delayed Quote. Delayed  - 09/30 10:00:00 pm
4.96 USD   +5.53%
09/17 OSIRIS THERAPEU : Provides Update Regarding NASDAQ Listing Status
09/16 Osiris Provides Update Regarding NASDAQ Listing Status
08/18 OSIRIS THERAPEU : Provides Update Regarding NASDAQ Listing Matters
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/26/2016 09/27/2016 09/28/2016 09/29/2016 09/30/2016 Date
4.69(c) 4.72(c) 4.83(c) 4.7(c) 4.96(c) Last
47 016 76 154 42 305 35 090 108 884 Volume
-1.88% +0.64% +2.33% -2.69% +5.53% Change
More quotes
Financials ($)
Sales 2015 97,5 M
EBIT 2015 6,80 M
Net income 2015 4,90 M
Debt 2015 -
Yield 2015 -
Sales 2016 -
EBIT 2016 -
Net income 2016 -
Debt 2016 -
Yield 2016 -
P/E ratio 2015 35,43
P/E ratio 2016 -
Capi. / Sales2015 1,75x
Capi. / Sales2016 -
Capitalization 171 M
More Financials
Company
Osiris Therapeutics, Inc. engages in stem cell research and development of pharmaceutical products.Its regenerative medicine targets dermal burns, pressure ulcers, venous leg, diabetic foot ulcers, and tissue and bone repair.The company was founded by Peter A. Friedli and James S. Burns on December... 
More about the company
Latest news on OSIRIS THERAPEUTICS, INC.
09/17 OSIRIS THERAPEUTICS : Provides Update Regarding NASDAQ Listing Status
09/16 OSIRIS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continue..
09/16 Osiris Provides Update Regarding NASDAQ Listing Status
08/18 OSIRIS THERAPEUTICS : Provides Update Regarding NASDAQ Listing Matters
08/17 OSIRIS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continue..
08/17 Osiris Provides Update Regarding NASDAQ Listing Matters
08/05 OSIRIS THERAPEUTICS : Grafix Manuscript Reporting Positive Outcomes of Multicent..
08/04 Grafix® Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex..
06/29 OSIRIS THERAPEUTICS : Change in Directors or Principal Officers, Financial State..
06/14 OSIRIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06/10 Osiris chief resigns for medical reasons
06/03 Mesoblast trading halt to stay in place until June 10, bad news expected
06/03 Is It Time To Invest In Stem Cell Biotechs?
05/31 Midday Gainers / Losers
05/31 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Advertisement
Chart OSIRIS THERAPEUTICS, INC.
Duration : Period :
Osiris Therapeutics, Inc. Technical Analysis Chart | OSIR | US68827R1086 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus
Number of Analysts 1
Average target price 4,00 $
Spread / Average Target -19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David A. Dresner President & Chief Executive Officer
Peter A. Friedli Chairman
Frank D. Czworka Chief Operating Officer
Gregory I. Law Chief Financial Officer, Secretary & Treasurer
Alla Danilkovitch Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OSIRIS THERAPEUTICS, I..-52.22%171
AMGEN, INC.2.76%124 834
GILEAD SCIENCES, INC.-21.81%104 411
CELGENE CORPORATION-12.72%81 023
REGENERON PHARMACEUTIC..-25.95%42 330
VERTEX PHARMACEUTICALS..-30.69%21 609
More Results